A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
The brain communicates chemically through dozens of neurotransmitters, each with characteristic pathways and behavioral effects. Glutamate is the primary excitatory transmitter; GABA is the primary inhibitor. Dopamine modulates reward, motivation, and motor control; serotonin influences mood, sleep, and appetite; norepinephrine mediates arousal and stress; acetylcholine is critical for memory and muscle activation. Each system has specific synthesis, release, receptor, and reuptake/degradation machinery that can be targeted pharmacologically.
Learn each major system as a package: pathway anatomy, function, associated disorders, and drugs that target it. Dopamine pathways (mesolimbic, nigrostriatal, mesocortical) and their links to schizophrenia, Parkinson's, and addiction are high-yield case studies.
You already know from synaptic transmission that neurons communicate by releasing chemical messengers across the synaptic cleft, where they bind receptors on the postsynaptic cell. Neurotransmitter systems extend this picture by asking: which chemicals are being released, where in the brain, and what behavioral effects do they produce? The answer is a rich landscape of distinct systems, each with its own geography, function, and clinical significance.
The most widespread transmitters are glutamate and GABA. Glutamate is the brain's main excitatory signal — it drives firing throughout cortex, hippocampus, and most other regions. GABA is the primary inhibitory signal, preventing runaway excitation and shaping the timing of neural activity. Nearly every region of the brain uses both; an imbalance between them underlies conditions from epilepsy (too little GABA) to the anxiolytic effects of benzodiazepines (which enhance GABA). These two transmitters are not dramatic in their individual behavioral effects — they are the infrastructure.
Modulatory systems are smaller in neuron count but enormous in behavioral impact. Dopamine neurons originating in the ventral tegmental area and substantia nigra project to limbic, cortical, and striatal targets, mediating reward prediction, motivation, and motor planning. Serotonin neurons, concentrated in the raphe nuclei, project diffusely throughout the brain and modulate mood, appetite, sleep, and impulsivity — though always through specific receptor subtypes, not as a uniform happiness signal. Norepinephrine from the locus coeruleus modulates arousal, attention, and the stress response. Acetylcholine is released by the basal forebrain into hippocampus and cortex to support memory encoding, and at the neuromuscular junction to drive muscle contraction.
Each system is a pharmacological target because drugs can intervene at every step: synthesis, storage in vesicles, release, receptor binding, and reuptake or enzymatic degradation. SSRIs block serotonin reuptake; L-DOPA is a dopamine precursor used in Parkinson's; benzodiazepines potentiate GABA. But pharmacological effects are rarely simple. The brain actively regulates its own sensitivity — receptors upregulate or downregulate, autoreceptors provide feedback, and adaptive changes accumulate over time. This is why antidepressants take weeks to work and why drugs of abuse require escalating doses over time.
Understanding these systems as integrated packages — pathway anatomy, receptor subtypes, associated functions, linked disorders, and drug mechanisms — is the foundation for biological psychiatry, psychopharmacology, and cognitive neuroscience. Each major system is its own chapter; the task now is to learn each one in enough depth to reason about what happens when it is dysregulated or pharmacologically perturbed.